RE: RNS27 Sep 2018 09:35
Ross Group Chairman & CEO, Barry Richard Pettitt, made the following statement:
"This is an excellent acquisition for Ross Group Plc and its shareholders, which I see as being the starting point of a new development to our existing business for the Group and the opportunity for Mari Signum and Prometheus to become one of the leading supply chain providers of Chitin. I would also like to welcome all our new Executive and Non-Executive Directors to our Group management team and, in particular, I am very honoured to have Professor Georg Holländer to join as our Senior Independent Non-Executive Director. Professor Holländer is the current Hoffmann and Action Medical Research Professor of Developmental Medicine at Oxford University and is an expert in the field where Chitin has potential biomedical applications.."